Last reviewed · How we verify
NCT06274411: ECMO-READY
Standby Cannulated ECMO for High-Risk Percutaneous Coronary Intervention
NA trial testing Standby cannulated ECMO in ECMO in 176 participants. Currently enrolling.
1 November 2026
Quick facts
| Lead sponsor | Beijing Anzhen Hospital |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 176 |
| Start date | 21 March 2025 |
| Primary completion | 1 November 2026 |
| Estimated completion | 1 December 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Standby cannulated ECMO
- Prophylactic ECMO
Conditions studied
- ECMO — all drugs for ECMO →
- High-risk PCI — all drugs for High-risk PCI →
Sponsor
Beijing Anzhen Hospital
Who can join
18 and older, any sex, with ECMO or High-risk PCI. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this multicenter, randomized trial is to compare standby cannulated ECMO versus prophylactic ECMO in patients undergoing high-risk percutaneous coronary intervention (PCI). The main question it aims to answer is : • If standby cannulated ECMO as compared with prophylactic ECMO will improve the outcomes in patients undergoing high-risk PCI
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Extracorporeal Membrane Oxygenation to Support the Circulation in Interventional Cardiac Procedures.
Brewer JM, Maybauer MO. · · 2024 · PMID 38963352 · DOI 10.4103/aca.aca_122_24
Verify or expand the search:
- PubMed search for NCT06274411
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for ECMO
Currently open trials in the same condition.
- NCT06872021 — Early Intra-aortic Balloon Pump Use After Venoarterial Extracorporeal Membrane Oxygenation · NA · recruiting
- NCT07193719 — Influence of Personalized Lung Volume Optimization Maneuver on Lung Function and Cardiac Performance in Children · Phase 1, PHASE2 · recruiting
- NCT06560164 — Restrictive Versus Liberal Thresholds for RBC Transfusion in ECMO · NA · recruiting
- NCT06676085 — A Novel Strategy of ECMO Management Using Nafamostat for Regional Combined With Low Intensity Systematic Anticoagulation · NA · recruiting
Other Beijing Anzhen Hospital trials
Trials by the same sponsor.
- NCT07521488 — LLM-Based Intelligent Health Management Assistant in Life-Cycle Health Management of Cardiac Surgery Patients · NA · not yet recruiting
- NCT07470814 — Multidisciplinary Collaborative Care System for Acute Myocardial Infarction Complicated With Cardiogenic Shock · not yet recruiting
- NCT07444372 — Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation · NA · not yet recruiting
- NCT07256197 — PCSK9 Inhibitors in the Treatment of Calcific Aortic Stenosis · Phase 3 · not yet recruiting
- NCT07485101 — Glycemic Targets During CPB in Elderly Diabetes · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06274411 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Anzhen Hospital
- Last refreshed: 25 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06274411.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing